PMID: 42224Oct 20, 1979

A double blind cross-over study with mepindolol-sulfate in patients with coronary heart disease (author's transl)

Wiener medizinische Wochenschrift
J BonelliG Kaik

Abstract

The effect of mepindolol-sulfate (2 x 2.5 mg) was tested in 20 patients with coronary heart disease in a controlled study against placebo resp. propranolol (3 x 40 mg). 1. The frequency and intensity of anginal attacks were reduced significantly under mepindolol-sulfate therapy.-- 2. There was a significant improvement of ergometric exercise tolerance under mepindolol-sulfate therapy.--3. Additionally a reduction of ST-depression in ECG was found under mepindolol-sulfate.--4. In patients with coronary heart disease the clinical effect of mepindolol-sulfate in a daily dose of 2 x 2.5 mg was equal to propranolol in a daily dose of 3 x 40 mg.

Related Concepts

Myocardial Contraction
Visken
Anginal Attack
Coronary Arteriosclerosis
Mepindolol
Drug Evaluation
Respiratory, Thoracic and Mediastinal Disorders
Propranolol
Rexigen
Half-Life

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.